

Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in high-risk populations, Spain, 2016

Xavier Martínez-Gómez¹, Adrian Curran², Magda Campins¹, Laia Alemany³, José Ángel Rodrigo-Pendás¹, Natalia Borruel⁴, Xavier Castellsagué³, Cristina Díaz-de-Heredia⁵, Fernando A Moraga-Llop⁶, Marta del Pino^{7,8}, Aureli Torné^{7,8}

1. Servei de Medicina Preventiva i Epidemiologia, Hospital Universitari Vall d'Hebron – Universitat Autònoma de Barcelona, Barcelona, España
2. Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron – Universitat Autònoma de Barcelona, Barcelona, España
3. Programa de Recerca en Epidemiologia del Càncer, Institut Català d'Oncologia – IDIBELL CIBER Epidemiologia y Salud Pública, Barcelona, España
4. Unitat d'Atenció Crohn-Colitis, Servei d'Aparell Digestiu; Hospital Universitari Vall d'Hebron – Universitat Autònoma de Barcelona, Barcelona, España
5. Servei d'Oncologia i Hematologia Pediàtrica, Hospital Universitari Vall d'Hebron - Universitat Autònoma de Barcelona, Barcelona, España
6. Asociación Española de Vacunología, Barcelona, España
7. Unidad de Ginecología Oncológica, Instituto Clínico de Ginecología y Obstetricia y Neonatología (ICGON), Hospital Clínic de Barcelona, Barcelona, España
8. Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Facultad de Medicina, Universidad de Barcelona, Barcelona, España

Correspondence: Magda Campins (mcampins@vhebron.net)

Citation style for this article:

Martínez-Gómez Xavier, Curran Adrian, Campins Magda, Alemany Laia, Rodrigo-Pendás José Ángel, Borruel Natalia, Castellsagué Xavier, Díaz-de-Heredia Cristina, Moraga-Llop Fernando A, del Pino Marta, Torné Aureli. Multidisciplinary, evidence-based consensus guidelines for human papilloma virus (HPV) vaccination in high-risk populations, Spain 2016. *Euro Surveill.* 2019;24(7):pii=1700857. <https://doi.org/10.2807/1560-7917.ES.2019.24.7.1700857>

Article submitted on 22 Dec 2017 / accepted on 15 Oct 2018 / published on 14 Feb 2019

Introduction: Although human papillomavirus (HPV) routine vaccination programmes have been implemented around the world and recommendations have been expanded to include other high-risk individuals, current recommendations often differ between countries in Europe, as well as worldwide. **Aim:** To find and summarise the best available evidence of HPV vaccination in high-risk patients aiding clinicians and public health workers in the day-to-day vaccine decisions relating to HPV in Spain. **Methods:** We conducted a systematic review of the immunogenicity, safety and efficacy/effectiveness of HPV vaccination in high-risk populations between January 2006 and June 2016. HPV vaccination recommendations were established with levels of evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. **Results:** A strong recommendation about HPV vaccination was made in the following groups: HIV infected patients aged 9–26 years; men who have sex with men aged 9–26 years; women with precancerous cervical lesions; patients with congenital bone marrow failure syndrome; women who have received a solid organ transplant or hematopoietic stem cell transplantation aged 9–26 years; and patients diagnosed with recurrent respiratory papillomatosis. **Conclusions:** Data concerning non-routine HPV vaccination in populations with a high risk of HPV infection and associated lesions were scarce. We have

developed a document to evaluate and establish evidence-based guidelines on HPV vaccination in high-risk populations in Spain, based on best available scientific evidence.

Introduction

Human papillomavirus (HPV) is the main cause of uterine cervical cancer (UCC) and its precursor lesions [1,2]. HPV can also be found in cancerous and precancerous lesions of the vulva and vagina [3,4], penis [5] anus [6], oropharyngeal cancer [7], anogenital warts [8] and recurrent respiratory papillomatosis (RRP) [9]. Nearly 90% of all female genital HPV infections are transient and resolve on their own in the next 2 years [10]. Persistence of HPV happens in 10% of infected healthy women and 1% of them will develop neoplastic HPV-related lesions. In men, duration and persistence of HPV infections are shorter than in women [11].

The estimated impact of newly diagnosed cases of HPV-related disease is high around the world: annually there are 30.9 million cases of cervical precancerous lesions, 32 million cases of genital condylomata and 630,000 cases of cancer (cervix, vagina, vulva, anus, penis, oropharyngeal, oral cavity and larynx) diagnosed [12,13].

Box

Individuals at high risk of human papillomavirus infection and related diseases, Spain, January 2006–June 2016

- HIV infected patients
- MSM
- Inflammatory bowel disease patients
- Women with precancerous cervical lesions
- Patients with congenital bone marrow failure syndrome, primary immunodeficiency or survivors of childhood neoplasia
- Solid organ or haematopoietic stem cell transplant recipients
- Patients with immunosuppressive or biological treatment
- Patients with recurrent respiratory papillomatosis

HIV: Human immunodeficiency virus; HPV: human papillomavirus; MSM: men who have sex with men.

HPV vaccination is an effective primary intervention to prevent HPV infection and its associated disease burden. Vaccination is used as part of a coordinated strategy with quality screening programmes and treatment services in cervical cancer prevention [14]. Three HPV vaccines containing virus-like particles (VLPs) are currently available: the bivalent vaccine (VLPs of high-risk HPV genotypes 16 and 18) [15]; the quadrivalent vaccine (VLPs of genotypes 6, 11, 16 and 18) [16]; and the nonavalent vaccine (VLPs of genotypes 6, 11, 16, 18, 31, 33, 45, 52 and 58) [17].

In the first decade of HPV vaccine use, the main strategy worldwide was routine vaccination programmes for adolescent and young women. In Europe, according to European Centre for Disease Control (ECDC) information reviewed in 2018, routine vaccination is included in the national immunisation schedule in the majority of countries ($n = 29$, 93.5%) [18]. In some countries, vaccine recommendations were later extended to include specific high-risk groups as the United States (US) where three doses of HPV vaccine are recommended for: (i) females and males aged 9–26 years with primary or secondary immunocompromising conditions that may reduce cell-mediated or humoral immunity, (ii) men who have sex with other men (MSM), (iii) transgender persons aged 9–26 years, (iv) individuals not adequately vaccinated and, (v) children with a history of sexual abuse [19,20]. In Australia MSM and immunocompromised individuals are included [21] and in Canada individuals with abnormal cervical cytology or a history of UCC and/or genital warts, MSM and immunocompromised individuals [22] are included too. Currently, no global European recommendations for

specific groups are mentioned [18] but some countries have begun to develop programmes [23].

In clinical practice, there is growing interest in expanding vaccine recommendations to patients at high-risk of HPV infection and development of related neoplasms. Currently, information on HPV vaccination for these high-risk populations is scarce and recommendations for selective vaccination differ between countries in Europe. Several reasons may explain the lack of guidelines for vaccination in high-risk populations, including: heterogeneity in the definition e.g. age, sex, disease characteristics and variations in the risk of infection, persistence or malignancy; limited published clinical trial data (due to difficulties in conducting appropriately powered studies on vaccine immunogenicity, safety and efficacy in individuals with low-incidence diseases); and limitations associated with establishing recommendations for patient groups not included in the product label. Some of these issues can be viewed in the Supplementary material.

A guideline on HPV vaccination in high-risk individuals, based on the review of current evidence by an independent and multidisciplinary expert panel, was recently released by the Spanish Association of Cervical Pathology and Colposcopy [24]. This paper summarises this evidence-base and process and depicts the guideline.

Methods

In October 2015, a steering committee was formed in Spain to compile this guideline after a rigorous review of the HPV-associated disease burden and a systematic review of studies investigating the immunogenicity, safety and efficacy of HPV vaccination in high-risk populations. This committee consisted of 10 Spanish professionals including gynaecologists, epidemiologists, paediatricians, infectologists, haematologists, gastroenterologists and preventive medicine specialists with recognised expertise in the area.

Selection criteria

This review included both randomised controlled trials (RCT) and observational studies (e.g. cohort studies, case reports) that assessed the effects of HPV vaccination on high-risk groups.


Based on clinical expertise of the steering committee and published literature, the following groups were defined as individuals at high-risk of HPV infection and HPV-related disease and were included in the guideline on HPV vaccination in high-risk individuals (Box).

The interventions of interest were the bivalent (Cervarix), quadrivalent (Gardasil) and nonavalent (Gardasil 9) HPV vaccines. The outcomes of interest were the efficacy, effectiveness, immunogenicity and safety of HPV vaccines.

Studies that did not report original data e.g. editorials or reviews were excluded.

FIGURE

Flowchart of literature selection for review of human papillomavirus vaccination in high-risk populations, Spain, January 2006–June 2016



HIV: Human immunodeficiency virus.

Search strategy

An electronic search was carried out using PubMed to find studies published in English from January 2006 to June 2016. The search terms were a combination of the names and synonyms of the different risk groups, the HPV vaccines and the outcomes of interest. The details of the search strategies are presented in the Supplementary material.

All authors conducted unstructured electronic searches and reviewed their personal files for relevant published papers.

Selection process

Two authors (XMG and JARP) independently screened the titles and abstracts of the articles identified by the PubMed search and selected articles for full-text reading in accordance with the selection criteria. Full texts for the relevant references were independently evaluated by XMG and JARP to determine their inclusion. Reference lists of included articles were screened to consider further potentially eligible studies (Figure). Any discrepancies in study selection were resolved by

discussion between the reviewers until a consensus was reached.

The agreement between reviewers in the selection process was computed using Stata/SE 14.2 for Windows (StataCorp LLC, College Station, Texas) and resulted in agreement of qualitative measures (Cohen's Kappa=0.98) [25].

Panel subgroups reviewed the initial literature search, selected references, evaluated evidence, drafted recommendations and summarised the evidence for each section. The content of the guideline was decided by the consensus panel; the evidence evaluation process involved a systematic weighting of the quality of evidence and the grade of recommendation using the Infectious Diseases Society of America (IDSA) version of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system [26,27].

The developed guideline for Spain was reviewed and endorsed by several groups acknowledged at the end of the article.

Results

Human immunodeficiency virus (HIV) infection

The prevalence of HPV infection in individuals with HIV infection is high [28-30]. Within this population, the number of sexual partners increases the risk of infection and reinfection for multiple HPV genotypes and decreases the probability of HPV clearance [29]. Compared with the general population, the persistence of HPV in people living with HIV significantly increases the risk of HPV-related cancers and condylomata.

Three risk subgroups can be identified in the overall HIV-infected population: HIV-infected women, HIV-infected men who have sex exclusively with women (MSW) and HIV-infected MSM. While UCC screening programmes and the improvement in HIV disease control have led to a decrease in the incidence of UCC in HIV-infected women, the incidence of anal cancer in this population is 30 per 100,000 person-years (US, 1996-2007) [31], and the prevalence of condylomata is 5-7% vs 1% in the general population (US, 1991-1998) [32,33]. In line with this, HIV-infected MSW in the US during 1996-2007 have an incidence of anal cancer that was significantly higher compared with men without HIV infection (46 vs two/100,000 person-years) [31]. The prevalence of condylomata in HIV-infected MSW in Spain from 2005 to 2009 was 15% [34]. The incidence of anal cancer in the US during 1996-2007 is especially high in MSM with HIV (131/100,000 person-years; rate ratio=80.3 compared with men without HIV) [31], and the prevalence of condylomata in HIV-infected MSM in Spain from 2005 to 2009 was 28% [34].

Rationale for recommendations

Nine papers of HPV vaccination in HIV population were selected [35-43]. Available data on the immunogenicity and safety of HPV vaccines in people with HIV infection support its use for the prevention of HPV-related cancers and genital warts; however, there are limited data on the efficacy of the vaccine (Supplementary material Table S1).

The efficacy results obtained in RCT of MSM [44] cannot be generalised to the HIV population, since the characteristics of the included individuals (age 16–26 years; ≤5 lifetime sexual partners; no history of sexually transmitted infections) differ from the majority of MSM with HIV seen in clinical practice. Prospective, RCT evaluating the efficacy of HPV vaccines in the prevention of recurrence in people with HIV receiving treatment for condylomata or premalignant lesions are ongoing [45-47].

Ideally, people with HIV who receive a HPV vaccine should be on antiretroviral treatment and have good immune-virological control at the time of vaccination.

Summary of previous guidelines or consensus recommendations

The European Acquired Immune Deficiency Syndrome (AIDS) Clinical Society guidelines recommend HPV vaccination in all individuals with HIV; however, they state that in situations where there is an established HPV infection, vaccine efficacy is questionable [48]. The US guidelines recommend vaccination for HIV females and males through age 26 years [19,20,49].

The 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host, recommends the administration of three-dose of quadrivalent HPV (qHPV) vaccine for females and males with HIV aged 11–26 years [27].

Recommendations in HIV patients

HPV vaccination is recommended in both male and female individuals with HIV from 9–26 years (quality of evidence: moderate; recommendation: strong). HIV-positive people aged 26 years and older could also benefit from HPV vaccination (quality of evidence low; recommendation: weak). The use of any of the available vaccines is indicated, although the quadrivalent or nonavalent vaccines are preferred given the high prevalence of anogenital warts in these patients.

Men who have sex with men

MSM have a high risk of HPV infection and HPV-related disease than MSW [50], with the incidence of anal neoplasia being nearly 20 times higher in MSM [51]. The annual recurrence rate of high-grade anal lesions following treatment may be up to 50% [52]. Data from the US suggest that MSM have a higher rate of condyloma than women do, but a lower rate than MSW [53].

Rationale for recommendations

Six papers of HPV vaccination in MSM population were selected (Supplementary material Table S2). One study evaluated the immunogenicity, efficacy and safety of the qHPV vaccine against HPV in healthy males aged 16–26 years [54]. Of the 4,065 men enrolled in the study, 602 were MSM. Antibody GMTs were lower in MSM vs MSW [55]. In MSM, the efficacy of the vaccine for prevention of persistent genital infection by any of the genotypes in the vaccine was 43.6%, while the efficacy for the prevention of persistent anal infection by HPV 6, 11, 16 or 18 was 94.9% [44,54]. The vaccine was effective in preventing 77.5% of the high-grade squamous intraepithelial lesions (HSIL)/anal intraepithelial neoplasia (AIN) secondary to HPV 6, 11, 16 or 18, and 70.2% of the genital warts [44].

The qHPV vaccine has also been evaluated in MSM patients aged 26 years or older. It was effective in the prevention of anal condyloma in a study of 313 MSM without story of anal condyloma or with history of previous HPV-related anal condyloma who had been recurrence-free for at least 12 months (hazard ratio=0.45; $p < 0.05$) [56]; it also reduced the incidence of HSIL (AIN) in another study of 202 MSM aged 18 years and older (83.7% of them aged over 30 years) who were treated for histologically confirmed HSIL (AIN) [57]. The recurrence rate of HSIL (AIN) in vaccinated MSM vs those not vaccinated was 10.2 vs 15.7 per 100 person-years [57].

One study assessed the immunogenicity and safety of the nonavalent vaccine vs placebo [58]. This trial included 313 MSM aged 16–26 years in addition to 1,106 MSW and 1,101 women who had neither received previous HPV vaccination nor had history of HPV-related lesions. The per-protocol analysis showed that, in MSM, the seroconversion rate for different HPV types was 99.5–100%; the GMTs in MSM were lower compared with MSW and women (ratio of 0.6–0.8 and 0.7–0.9, respectively, depending on the genotype analysed) [58]. Data on the efficacy of HPV vaccination for prevention of lesions are not available. No specific data on the safety of HPV vaccines in the MSM population were described in most of the studies evaluated.

Summary of previous guidelines or consensus recommendations

The Advisory Committee on Immunisation Practices (ACIP) recommends routine HPV vaccination for MSM aged 9–26 years, including transgender persons [20].

Recommendations in men who have sex with men

HPV vaccination is recommended in MSM aged 9–26 years (quality of evidence: moderate; recommendation: strong). MSM aged 26 years and older may also benefit from HPV vaccination (quality of evidence: very low; recommendation: weak). The use of any of the available vaccines is indicated, although the quadrivalent or nonavalent vaccines are preferred given the high prevalence of anogenital warts in MSM.

Inflammatory bowel disease

Treatment of inflammatory bowel disease IBD (Crohn's disease and ulcerative colitis) often includes immunosuppressants, which increase the risk of HPV persistence. Compared with patients not receiving immunosuppressive treatment, patients with IBD receiving azathioprine show a higher incidence of cutaneous warts and skin and genital herpes flares [59]. Although some studies have reported the development or worsening of genital condyloma in patients with IBD treated with anti-tumour necrosis factor (TNF) antibodies such as infliximab and etanercept [60,61], other studies suggest no relationship between the use of TNF antibodies and persistent HPV infection [62].

Controversy remains regarding to the increased risk of HPV infection and UCC in patients with IBD vs the general population. A study of 40 patients with IBD showed a higher incidence of abnormal cervical cytology in women with IBD compared with similar healthy controls (42% vs 7%; $p < 0.001$), and a higher incidence of lesions [63]. In this study, the use of immunosuppressants for at least 6 months was also associated to an increased risk of abnormal cytology (Odds ratio (OR): 1.5; 95% confidence interval (CI): 1.2–4.1; p value = 0.021) [63]. A study of 116 women with IBD showed an increased rate of abnormal cervical cytology [64], while a population-based study of patients with Crohn's disease demonstrated an increased risk of UCC and dysplasia [65]. Another study showed an increased risk of both low-grade squamous intraepithelial lesions (LSIL), HSIL and UCC in patients with IBD vs a control group (incidence rate ratio for UCC in Crohn's disease: 1.53; 95% CI: 1.04–2.27) [66]. Case–control studies have not shown an increased risk of histological or cytological cervical abnormalities in women with IBD [67,68].

Rationale for recommendations

One paper of HPV vaccination in IBD population was selected (Supplementary material Table S3). One study investigating the profile of the qHPV vaccine in patients with IBD showed an adequate immunogenicity and safety profile [69]. Similar antibody titres were induced in patients with IBD and healthy controls, although 49% of the IBD patients were receiving immunosuppressants and 51% were receiving anti-TNF antibodies. Some major adverse events were detected (exacerbations of IBD ($n = 2$), pneumonia ($n = 1$), ovarian torsion ($n = 1$), acute sinus pain ($n = 1$)), but none of them appeared to be related to HPV vaccination.

Summary of previous guidelines or consensus recommendations

All guidelines regarding prevention of opportunistic infections in patients with IBD recommend regular clinical screening and HPV vaccination, particularly in patients receiving immunosuppressants [70–73].

Recommendations in inflammatory bowel disease patients

HPV vaccination is recommended for women with IBD aged 9–26 years (quality of evidence: low; recommendation: weak). Although vaccination can be administered at any time, it is preferable to vaccinate at the time of diagnosis and before the use of immunosuppressive or biological therapies, to ensure higher immunogenicity. There are no data supporting HPV vaccination in men with IBD.

Women with HPV infection and precancerous cervical lesions

In Spain, a large-scale study estimate that the prevalence of HPV infection is 13.4% and 7.9% in women aged 26–45 and 46–65 years, respectively, compared with 28.8% in women aged 18–25 years [74]. Rates of precancerous cervical lesions are reported between 0.4 and 0.7%; the estimated number of women aged 18 years or older with HSIL (CIN) in Spain is in the range of 54,087–92,423 [75].

Rationale for recommendations

A substantial proportion of adult women become infected with HPV, particularly genotypes 16 and 18. The probability of persistence increases with age, which consequently increases the risk of precancerous lesions or UCC developing. Women with precancerous cervical lesions have a 5–25% risk of recurrence and an increased risk of developing UCC compared with the general population [76]. This increased risk is mainly due to persistent HPV. Moreover, while in general the HPV infection clears after treatment, natural immunity does not provide complete protection against reactivation or reinfection by the same HPV genotype [75].

Three papers of HPV vaccination in women with HPV infection and precancerous cervical lesions were selected (Supplementary material Table S4). Precancerous lesions are generally diagnosed in women aged 25 years or older; data about HPV vaccination in this group of women are limited. However, a few studies focused on adult women and showed that both qHPV vaccine and the bivalent HPV vaccine are immunogenic, effective and safe in this age group [77,78]. Immunisation with the qHPV vaccine resulted in 64.9% (95% CI: 20.1–86.3) efficacy in preventing new cervical lesions by any HPV genotype in treated women [79]. Another study of 737 women undergoing cervical conisation showed that the qHPV vaccine was associated with a 65% reduction in HPV recurrence at 2 years, regardless of genotype (2.5% vs 7.2% recurrences in vaccinated and unvaccinated women, respectively) [80]. The post-treatment risk reduction of new lesions following bivalent vaccine immunisation in women with surgically treated cervical lesions was 88.2% (95% CI: 14.8–99.7), regardless of genotype [81]. These studies demonstrate that HPV vaccination in women with cervical lesions who undergo treatment results in a significant reduction in the risk of new lesions. No specific

safety data on the HPV vaccines in these populations was identified in any of the studies evaluated.

Summary of previous guidelines or consensus recommendations

In Spain, a consensus guideline from several scientific societies recommends HPV vaccination in sexually active women. Because of the increased risk of HPV infection and increased persistence of infection with age in women with prior HPV infection and viral clearance, the intention of this recommendation is to protect against reinfection and to reduce the risk of developing new lesions and UCC in women receiving treatment for cervical lesions [75].

Recommendations in women with HPV infection and precancerous cervical lesions

HPV vaccination is recommended in women undergoing treatment for precancerous cervical lesions (quality of evidence: moderate; recommendation: strong). Patients with precancerous cervical lesions who have not yet been treated, may benefit from HPV vaccination (quality of evidence: low; recommendation: strong). Ideally, the vaccine should be administered early, either at diagnosis or before cervical conisation.

Congenital bone marrow failure syndrome, primary immunodeficiency or survivors of childhood neoplasia

Congenital bone marrow failure syndrome (CBMFS) is a group of heterogeneous diseases associated with inadequate blood cell production, constitutional malformations and predisposition to cancer. Patients with Fanconi's anaemia and dyskeratosis congenita, both congenital bone marrow failure syndromes, are at risk of gynaecological and head and neck squamous cell carcinomas [82]. The increased risk of cancer in these patients means that cancer prevention strategies are essential.

Certain primary immunodeficiency conditions, such as epidermodysplasia verruciformis, hyper-IgE syndrome, idiopathic CD4 lymphopaenia, GATA2 deficiency and Warts-hypogammaglobulinaemia, infections and myelokathesis (WHIM) or Netherton's syndrome, have the presence of cutaneous warts as one of the main clinical manifestations of the disease [83]. Patients with these conditions are more susceptible to persistent HPV infection because of an impaired immune response to the virus, an increased risk of extensive skin involvement and a higher risk of precancerous cervical lesions progressing to malignancy.

Survivors of childhood, adolescent or young adulthood cancer e.g. Hematopoietic stem cell transplantation (HSCT) recipients, post-transplant survivors with chronic graft-vs-host disease receiving immunosuppressive therapy, individuals with a history of pelvic radiation and those with Hodgkin's lymphoma, are also at risk of adverse outcomes associated with HPV infection [84]. In one US study, male and female long-term

cancer survivors had 150% and 40% more HPV-related malignancies, respectively, than the general population [85].

Rationale for recommendations

Two papers of HPV vaccination in CBMFS, primary immunodeficiency or survivors of childhood neoplasia were selected (Supplementary material Table S5). Patients with Fanconi's anaemia and dyskeratosis congenita have a similar immune response to HPV vaccination to that of the general population [86].

While live-attenuated vaccines are not feasible in patients with primary immunodeficiency, inactivated or subunit vaccines are considered safe [87] and could play an important role in the prevention of both malignancy and warts. Immunisation of a WHIM patient with the qHPV vaccine induced neutralising antibodies and a cellular immune response, indicating that patients with WHIM syndrome may benefit from HPV vaccination [88]. No safety data were reported in any of the studies analysed. Although most survivors of childhood neoplasia recover their immunity within 6 months of the end of chemotherapy or immunosuppressive therapy, the immunogenicity to HPV vaccines in this population is not well known so additional studies are needed.

Summary of previous guidelines or consensus recommendations

ACIP recommends routine HPV vaccination to primary immunodeficiency patients aged 9–26 years [20]. The Children's Oncology Group recommends HPV vaccination for all female survivors of childhood cancer [89,90].

Recommendations in patients with congenital bone marrow failure syndrome, primary immunodeficiency or survivors of childhood neoplasia

HPV vaccination of patients with CBMFS is recommended (quality of evidence: low; recommendation: strong).

HPV vaccination may benefit patients with primary immunodeficiency (quality of evidence: very low; recommendation: weak). The use of any of the available vaccines is indicated, although the quadrivalent or nonavalent vaccines are preferred given the high prevalence of anogenital warts in these patients.

Survivors of childhood neoplasia can benefit from HPV vaccination (quality of evidence: very low; recommendation: weak).

Solid organ or haematopoietic stem cell transplantation

Patients who have undergone solid organ transplantation need life-long immunosuppressive therapy, which increases their risk of complications associated with persistent HPV infection. Studies have shown that immunosuppressed transplant recipients have an increased presence of HPV in the oral cavity, higher

prevalence of genital warts [91], high oncogenic HPV in squamous cell skin cancer [92], an increased risk of anal cancer [93-95] and UCC [96-98].

Patients who have undergone HSCT have an increased risk of developing solid organ cancer [99]. In some studies, this risk was double that of the general population [100,101]. The increase in survival after HSCT has been associated with an increased prevalence of HSIL in these women [102,103].

Rationale for recommendations

Three papers of HPV vaccination in solid organ or haematopoietic stem cell transplantation were selected [104-106] (Supplementary material Table S6). Epidemiological data show a high risk of gynaecological and other cancers in transplant recipients [102]. Limited data are available on the immunogenicity and efficacy of HPV vaccination in individuals who have undergone solid organ transplantation, and no information exists for HSCT recipients.

Summary of previous guidelines or consensus recommendations

ACIP recommends routine HPV vaccination for those aged 9–26 years for transplant patients [20].

The 2013 Infectious Diseases Society of America (IDSA) clinical practice guideline for vaccination of the immunocompromised host recommends that physicians consider the administration of three doses of HPV vaccine 6–12 months after HSCT for female patients aged 11–26 years and qHPV vaccine for males aged 11–26 years. The HPV vaccine series should also be administered to solid organ transplant candidates aged 11–26 years [27].

Recommendations in solid organ or haematopoietic stem cell transplant recipients

HPV vaccination is recommended in female transplant recipients aged 9–26 years (quality of evidence: low; recommendation: strong). Female patients aged 26 years and older may also benefit from HPV vaccination, particularly those with chronic graft vs host disease following HSCT (quality of evidence: very low; recommendation: weak). If possible, vaccination should be provided before solid organ transplantation and preferably before the use of immunosuppressive or biological therapies to ensure high immunogenicity. Vaccination is not recommended within 6 months post-transplantation. Patients undergoing HSCT should be vaccinated 6–12 months after transplantation, even if vaccinated beforehand.

Immunosuppressive or biological treatment

Immunosuppression is an important risk factor for cervical HPV infection [107]. HPV has a predilection for epithelial cells and causes an abnormal proliferation of keratinocytes, which may manifest as benign warts or malignant neoplasms. The host immune response to HPV infection is initiated by cytokines and chemokines

that are secreted by the virally stimulated keratinocyte. If the immune response is sufficient HPV lesions may regress, but this resolution of HPV lesions is not generally seen in the immunosuppressed patients resulting in severe, persistent and extensive manifestations of HPV disease [108]. Among patients undergoing therapeutic immunosuppression, evidence is restricted to some disease types e.g. systemic lupus erythematosus (SLE) or juvenile idiopathic arthritis (JIA) and rarely stratified by therapeutic modality or dosage.

Some studies have shown an increase in the prevalence of HPV infection, dysplasia and premalignant lesions in patients with SLE and those with kidney failure undergoing haemodialysis [107,109]. A systematic review of studies in patients with SLE concluded that they are at higher risk of cervical dysplasia and precancerous lesions. However, most studies show a similar prevalence of UCC in patients with SLE compared with the general population [110]. A delay in HPV clearance and a greater persistence of infection and HPV-associated lesions in SLE patients could be explained by alterations in the innate and adaptive immune response in this population [111]. However, the role of immunosuppressants as a predisposing factor to HPV-associated cervical lesions is unconfirmed [102,112].

TNF blockers are widely used to treat chronic inflammatory diseases. TNF plays an essential part in host defence and the immune response. Although uncommon, cases of extensive cutaneous HPV lesions have been reported following TNF blocking therapy [61,113,114].

Rationale for recommendations

The high rates of HPV infection and associated lesions in immunocompromised individuals justify the need to consider vaccination in this population [107]. Although published data are limited to some groups of patients, evidence suggests that women with SLE are at an increased risk of developing HPV-related lesions. As SLE is an immune disorder that predominantly affects women, most subjects in studies evaluating the risk of HPV infection and lesions in SLE patients are women [110].

Five papers of HPV vaccination in patients with immunosuppressive or biological treatment were selected. (Supplementary material Table S7) [115-119]. In the largest study, administration of the qHPV vaccine resulted in similar seroconversion rates to the general population 12 months post-vaccination [115]. Lower seroconversion rates were seen in patients receiving treatment with prednisolone or mycophenolate mofetil. There were no safety issues or an increased risk of SLE flares seen with vaccination [115].

Two studies evaluating the immunogenicity and safety of HPV vaccines in JIA patients have been published [118,119]. One was a prospective cohort study including 68 females aged 12–18 years with JIA who were

TABLE

Summary of recommendations regarding human papillomavirus vaccination in high-risk populations

High-risk population	Summary and recommendations	Quality of evidence	Recommendation strength
HIV infection	HPV vaccination is recommended in HIV patients through age 26, regardless of gender	Moderate	Strong
	HIV-positive patients aged ≥ 26 years may also benefit from HPV vaccination	Low	Weak
MSM	HPV vaccination in MSM through age 26 is recommended	Moderate	Strong
	MSM aged ≥ 26 years may benefit from HPV vaccination	Very Low	Weak
IBD	HPV vaccination is recommended in women with IBD through age 26	Low	Weak
Women with premalignant cervical lesions	HPV vaccination is recommended in women treated for precancerous cervical lesions	Moderate	Strong
	Women with untreatable intraepithelial lesions may benefit from HPV vaccination	Low	Strong
CBMFS	HPV vaccination is recommended in patients with CBMFS	Low	Strong
Primary immunodeficiency	Patients with primary immunodeficiency may benefit from HPV vaccination	Very low	Weak
Survivors of childhood neoplasia	Survivors of childhood cancer may benefit from HPV vaccination	Very low	Weak
Solid organ transplantation or HSCT	HPV vaccination is recommended in women through age 26 who have received a solid organ transplant or HSCT	Low	Strong
	Female patients aged ≥ 26 years may benefit from HPV vaccination, particularly those with chronic graft-vs-host disease after HSCT	Very low	Weak
Immunosuppressive or biological treatment	HPV vaccination is recommended in women receiving immunosuppressive and/or biological treatment through age 26 (in particular women with SLE or JIA)	Low	Weak
RRP	HPV vaccination is recommended in patients diagnosed with RRP through age 26	Low	Strong

CBMFS: congenital bone marrow failure syndrome; HIV: human immunodeficiency virus; HPV: human papillomavirus; HSCT: haematological stem cell transplantation; IBD: inflammatory bowel disease; JIA: juvenile idiopathic arthritis; MSM: men who have sex with men; RRP: recurrent respiratory papillomatosis; SLE: systemic lupus erythematosus.

vaccinated with bivalent HPV vaccine. The vaccine showed a strong HPV 16/18-specific antibody response that was comparable with the response seen in healthy female adolescents; HPV-specific geometric mean concentrations (GMCs) were consistently lower in JIA patients. No effect of methotrexate or anti-TNF treatment on the vaccine response was observed and no safety concerns were found [118]. Another prospective cohort study including 21 female patients with JIA aged 12–25 years and 21 healthy controls immunised with bivalent HPV vaccine showed significantly lower HPV 16 neutralising antibody titres in JIA patients than controls, but no significant difference in HPV-18 antibody titres. Immunoresponse to the vaccine did not seem to be affected by the type of anti-rheumatic therapy the patients were receiving. The vaccine was safe and well tolerated [119].

At present, there are no published data from randomised clinical trials on the efficacy, immunogenicity or safety of HPV vaccination in patients receiving immunosuppressive and/or biological treatment.

Summary of previous guidelines or consensus recommendations

The evidence-based recommendations on vaccination in patients with autoimmune rheumatic diseases from the European League against Rheumatism specify that HPV vaccination should be considered in women with SLE aged less than 26 years [120].

ACIP recommends routine HPV vaccination for immunosuppressed patients aged 9–26 years [20].

The 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host recommends HPV vaccination for females and males 11–26 years old with chronic inflammatory diseases on immunosuppressive medications [27].

Recommendations in patients receiving immunosuppressive or biological treatment

HPV vaccination is recommended in women receiving immunosuppressive and/or biological treatment aged 9–26 years, in particular, women with SLE or JIA (quality of evidence: low; recommendation: weak). While the vaccine can be given at any time, administration before

the use of immunosuppressive or biological therapies is preferable. There are no data supporting HPV vaccination in males receiving immunosuppressive or biological therapy.

Recurrent respiratory papillomatosis

Recurrent respiratory papillomatosis (RRP) is characterised by the presence of multiple papilloma in the airway that cause obstructive symptoms such as shortness of breath, hoarseness or stridor [121]. The disease may occur in children (aged ≤ 17 years) or adults [9,122]. The incidence of both juvenile and adult forms of RRP is estimated at 3–7 per 100,000 individuals [123,124]. HPV infection is the cause of RRP, with genotypes 6 and 11 present in 90–95% of cases [9].

Rationale for recommendations

Nine papers of HPV vaccination in patients with recurrent respiratory papillomatosis were selected (Supplementary material Table S8). No randomised clinical trials on the efficacy of HPV vaccine have been conducted in individuals with RRP. Several studies have investigated the effectiveness of the quadrivalent vaccine in both juvenile RRP [122,125–131] and adult RRP [122,126,130,132] (Supplementary material Table S8). Vaccination-induced partial or complete remission in a substantial proportion of the RRP patients, and no remarkable adverse effects were reported.

Summary of previous guidelines or consensus recommendations

There are no guideline or consensus documents that specifically recommend HPV vaccination in patients with RRP.

Recommendations in patients with RRP

HPV vaccination is recommended in patients with RRP aged 9–26 years (quality of evidence: low; recommendation: strong). Given the relationship of RRP to HPV genotypes 6 and 11, the use of the quadrivalent or nonavalent vaccine is recommended. Despite scarce data, the potential benefit should outweigh the risk of vaccination; therefore compassionate use may be considered in juvenile patients who are under the age indicated in the summary of product characteristics for the vaccine.

Summary of recommendations

Data concerning non-routine HPV vaccination in populations with a high risk of HPV infection and associated lesions are scarce, and recommendations differ between countries. The evidence-based recommendations for HPV vaccination in high-risk populations conducted by an independent expert panel are summarised in Table.

Conclusions

Systematic HPV vaccination is considered the most effective intervention for controlling the infection and preventing HPV-related disease burden. Along with other interventions, such as information, screening

and treatment, HPV vaccination is crucial in the prevention of uterine cervical cancer.

In all high-risk populations, based on the summary and recommendations, the quality of evidence was found to be very low to moderate. A strong recommendation about HPV vaccination was made in HIV infected patients aged 9–26 years; men who have sex with men aged 9–26 years; women with precancerous cervical lesions; patients with congenital bone marrow failure syndrome; women who have received a solid organ transplant or hematopoietic stem cell transplantation aged 9–26 years; and patients diagnosed with recurrent respiratory papillomatosis. In the rest of high-risk categories with only a weak recommendation (HIV-positive patients aged ≥ 26 years, MSM aged ≥ 26 , IBD, patients with primary immunodeficiency, survivors of childhood neoplasia, women who have received a solid organ transplant or hematopoietic stem cell transplantation aged ≥ 26 years and patients in immunosuppressive or biological treatment), the quality of evidence was low or very low. Further studies are needed.

Note

Author Xavier Castellsagué passed away 12 June 2016.

Acknowledgements

We would like to thank Sheridan Henness, PhD, and Sarah Greig, PhD, of Springer Healthcare Communications who wrote the outline and first draft of this manuscript. This medical writing assistance was funded by the Spanish Association of Cervical Pathology and Colposcopy (AEPCC).

The guideline on HPV vaccination in high-risk individuals was reviewed and endorsed by the Spanish Association of Cervical Pathology and Colposcopy (Asociación Española de Patología Cervical y Colposcopia (AEPCC)), the Spanish Association of Paediatrics (Asociación Española de Pediatría (AEP)), the Spanish Association of Vaccinology (Asociación Española de Vacunología (AEV)), the Spanish Society of Paediatric Haematology and Oncology (Sociedad Española de Hematología y Oncología Pediátricas (SEHOP)), the Spanish Society of Haematology and Haemostasis (Sociedad Española de Hematología y Hemoterapia (SEHH)), the Spanish Society of Primary Care Doctors (Sociedad Española de Médicos de Atención Primaria (SEMergen)), the Spanish Society of Community and Family Medicine (Sociedad Española de Medicina de Familia y Comunitaria (semFYC)), the Spanish Society of Preventive Medicine, Public Health and Hygiene (Sociedad Española de Medicina Preventiva, Salud Pública e Higiene (SEMPSPH)), the Study Group of Sexually Transmitted Diseases of the Spanish Society of Infectious Diseases and Clinical Microbiology (Grupo de Estudio de las Infecciones de Transmisión Sexual (GeITS) de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC)) and the Spanish Working Group in Crohn's Disease and Ulcerative Colitis (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)).

Conflict of interest

Several authors have received economical funds for research through their working institutions from Sanofi Pasteur MSD

and MSD and received speakers' fees from GSK and/or Sanofi Pasteur MSD and MSD.

Authors' contributions

All authors have contributed to bibliographic search, critical review of papers, GRADE classification of recommendations and manuscript writing. Xavier Martínez and José Ángel Rodrigo Pendás designed and carried out the electronic bibliographic search, selected the references for full-text reading after the screening of the title and abstract of all the studies retrieved and selected the papers finally included. Xavier Martínez and Magda Campins have also drafted the first version of the manuscript and have incorporated all the modifications recommended by the other authors.

References

1. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. *J Clin Pathol.* 2002;55(4):244-65. <https://doi.org/10.1136/jcp.55.4.244> PMID: 11919208
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J Pathol.* 1999;189(1):12-9. [https://doi.org/10.1002/\(SIC\)1096-9896\(199909\)189:1<12::AID-PATH431>3.o.CO;2-F](https://doi.org/10.1002/(SIC)1096-9896(199909)189:1<12::AID-PATH431>3.o.CO;2-F) PMID: 10451482
3. Alemany L, Saunier M, Tinoco L, Quirós B, Alvarado-Cabrero I, Alejo M, et al. HPV VVAP study group. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. *Eur J Cancer.* 2014;50(16):2846-54. <https://doi.org/10.1016/j.ejca.2014.07.018> PMID: 25155250
4. de Sanjosé S, Alemany L, Ordi J, Tous S, Alejo M, Bigby SM, et al. HPV VVAP study group. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. *Eur J Cancer.* 2013;49(16):3450-61. <https://doi.org/10.1016/j.ejca.2013.06.033> PMID: 23886586
5. Alemany L, Cubilla A, Halc G, Kasamatsu E, Quirós B, Masferrer E, et al. HPV VVAP study group. Role of Human Papillomavirus in Penile Carcinomas Worldwide. *Eur Urol.* 2016;69(5):953-61. <https://doi.org/10.1016/j.eururo.2015.12.007> PMID: 26762611
6. Alemany L, Saunier M, Alvarado-Cabrero I, Quirós B, Salmeron J, Shin HR, et al. HPV VVAP Study Group. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. *Int J Cancer.* 2015;136(1):98-107. <https://doi.org/10.1002/ijc.28963> PMID: 24817381
7. Castellsagué X, Alemany L, Quer M, Halc G, Quirós B, Tous S, et al. ICO International HPV in Head and Neck Cancer Study Group. HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. *J Natl Cancer Inst.* 2016;108(6):d1v403. <https://doi.org/10.1093/jnci/d1v403> PMID: 26823521
8. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. *J Infect Dis.* 2009;199(6):805-14. <https://doi.org/10.1086/597071> PMID: 19199546
9. Gillison ML, Alemany L, Snijders PJ, Chaturvedi A, Steinberg BM, Schwartz S, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. *Vaccine.* 2012;30(Suppl 5):F34-54. <https://doi.org/10.1016/j.vaccine.2012.05.070> PMID: 23199965
10. Castellsagué X. Natural history and epidemiology of HPV infection and cervical cancer. *Gynecol Oncol.* 2008;110(3) Suppl 2:S4-7. <https://doi.org/10.1016/j.ygyno.2008.07.045> PMID: 18760711
11. Giuliano AR, Anic G, Nyitray AG. Epidemiology and pathology of HPV disease in males. *Gynecol Oncol.* 2010;117(2) Suppl:S15-9. <https://doi.org/10.1016/j.ygyno.2010.01.026> PMID: 20138345
12. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. *Int J Cancer.* 2017;141(4):664-70. <https://doi.org/10.1002/ijc.30716> PMID: 28369882
13. Serrano B, Brotons M, Bosch FX, Bruni L. Epidemiology and burden of HPV-related disease. *Best Pract Res Clin Obstet Gynaecol.* 2018;47:14-26. <https://doi.org/10.1016/j.bpobgyn.2017.08.006> PMID: 29037457
14. World Health Organization (WHO). Human papillomavirus vaccines: WHO position paper, May 2017. *Wkly Epidemiol Rec.* 2017;92(19):241-68. PMID: 28530369
15. GlaxoSmithKline. Cervarix suspension for injection: summary of product characteristics: GlaxoSmithKline; 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000721/WC500024632.pdf
16. Merck Sharp & Dohme BV. Gardasil suspension for injection: summary of product characteristics. Stockholm: Merck Sharp & Dohme BV; 2011. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000703/WC500021142.pdf
17. Merck Sharp & Dohme BV. Gardasil 9 suspension for injection: summary of product characteristics. Merck Sharp & Dohme BV; 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003852/WC500189111.pdf
18. European Centre for Disease Prevention and Control (ECDC). Vaccine schedules in all countries of the European Union. Stockholm: ECDC. Available from: <http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx> [Accessed 3 Jul 2018].
19. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep.* 2014;63(RR-05):1-30. PMID: 25167164
20. Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CBA Advisory Committee on Immunization Practices. Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2017. *Ann Intern Med.* 2017;166(3):209-19. <https://doi.org/10.7326/M16-2936> PMID: 28166560
21. Australian Technical Advisory Group on Immunisation (ATAGI). The Australian immunisation handbook 10th ed (2015 update). Canberra: Australian Government Department of Health; 2015.
22. National Advisory Committee on Immunization (NACI). Update on the recommended Human Papillomavirus (HPV) vaccine immunization schedule. Ottawa: NACI; 2015. Available from: http://www.phac-aspc.gc.ca/naci-ccni/acs-dcc/2015/hpv-vph_0215-eng.php
23. Public Health England (PHE). Human papillomavirus (HPV) vaccination for Men who have sex with Men (MSM) 2016/17 pilot evaluation. London: PHE; 2016. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/678987/HPV_msm_year1_evaluation_report.pdf
24. Asociación Española de Patología Cervical Colposcopia (AEPCC). Vacunación selectiva frente al virus del papiloma humano en poblaciones de riesgo elevado. [Selective vaccination against human papillomavirus in high-risk populations]. AEPCC; 2016. Spanish. Available from: http://www.aepcc.org/wp-content/uploads/2016/12/AEPCC_revista07_VACUNACION-SELECTIVA.pdf
25. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics.* 1977;33(1):159-74. <https://doi.org/10.2307/2529310> PMID: 843571
26. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. *J Clin Epidemiol.* 2013;66(7):719-25. PMID: 23312392
27. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. *Clin Infect Dis.* 2014;58(3):e44-100. <https://doi.org/10.1093/cid/cit684> PMID: 24311479
28. Darwich L, Cañadas MP, Videla S, Coll J, Molina-López RA, Sirera G, et al. Can Ruti HIV-HPV Team. Prevalence, clearance, and incidence of human papillomavirus type-specific infection at the anal and penile site of HIV-infected men. *Sex Transm Dis.* 2013;40(8):611-8. <https://doi.org/10.1097/01.OLQ.0000430798.61475.08> PMID: 23859907
29. de Pokomandy A, Rouleau D, Ghattas G, Vézina S, Coté P, Macleod J, et al. HIPVIRG Study Group. Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. *J Infect Dis.* 2009;199(7):965-73. <https://doi.org/10.1086/597207> PMID: 19239366
30. Geskus RB, González C, Torres M, Del Romero J, Viciano P, Masiá M, et al. CoRIS-HPV Study Group. Incidence and clearance of anal high-risk human papillomavirus in HIV-positive men who have sex with men: estimates and risk factors. *AIDS.* 2016;30(1):37-44. PMID: 26355673
31. Silverberg MJ, Lau B, Justice AC, Engels E, Gill MJ, Goedert JJ, et al. North American AIDS Cohort Collaboration on Research

- and Design (NA-ACCORD) of leDEA. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. *Clin Infect Dis*. 2012;54(7):1026-34. <https://doi.org/10.1093/cid/cir1012> PMID: 22291097
32. Conley LJ, Ellerbrock TV, Bush TJ, Chiasson MA, Sawo D, Wright TC. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. *Lancet*. 2002;359(9301):108-13. [https://doi.org/10.1016/S0140-6736\(02\)07368-3](https://doi.org/10.1016/S0140-6736(02)07368-3) PMID: 11809252
 33. Massad LS, Silverberg MJ, Springer G, Minkoff H, Hessel N, Palefsky JM, et al. Effect of antiretroviral therapy on the incidence of genital warts and vulvar neoplasia among women with the human immunodeficiency virus. *Am J Obstet Gynecol*. 2004;190(5):1241-8. <https://doi.org/10.1016/j.ajog.2003.12.037> PMID: 15167825
 34. Darwich L, Cañadas MP, Videla S, Coll J, Piñol M, Cobarsi P, et al. HIV-HPV Can Ruti Team. Condylomata, cytological abnormalities and human papillomavirus infection in the anal canal in HIV-infected men. *HIV Med*. 2012;13(9):549-57. <https://doi.org/10.1111/j.1468-1293.2012.01013.x> PMID: 22435501
 35. Levin MJ, Moscicki AB, Song LY, Fenton T, Meyer WA 3rd, Read JS, et al. IMPAACT P1047 Protocol Team. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. *J Acquir Immune Defic Syndr*. 2010;55(2):197-204. <https://doi.org/10.1097/QAI.0b013e31818de8d26> PMID: 20574412
 36. Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N, et al. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. *Clin Infect Dis*. 2013;57(5):735-44. <https://doi.org/10.1093/cid/cit319> PMID: 23667266
 37. Giacomet V, Penagini F, Trabattoni D, Viganò A, Rainone V, Bernazzani G, et al. Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. *Vaccine*. 2014;32(43):5657-61. <https://doi.org/10.1016/j.vaccine.2014.08.011> PMID: 25149430
 38. Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K, et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. *Vaccine*. 2013;31(48):5745-53. <https://doi.org/10.1016/j.vaccine.2013.09.032> PMID: 24091311
 39. Kojic EM, Kang M, Cespedes MS, Umbleja T, Godfrey C, Allen RT, et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. *Clin Infect Dis*. 2014;59(1):127-35. <https://doi.org/10.1093/cid/ciu238> PMID: 24723284
 40. Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. *J Infect Dis*. 2010;202(8):1246-53. <https://doi.org/10.1086/656320> PMID: 20812850
 41. Toft L, Storgaard M, Müller M, Sehr P, Bonde J, Tolstrup M, et al. Comparison of the immunogenicity and reactivity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. *J Infect Dis*. 2014;209(8):1165-73. <https://doi.org/10.1093/infdis/jit657> PMID: 24273179
 42. Money DM, Moses E, Blitz S, Vandriel SM, Lipsky N, Walmsley SL, et al. HPV in HIV Study Group. HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine. *Vaccine*. 2016;34(40):4799-806. <https://doi.org/10.1016/j.vaccine.2016.08.016> PMID: 27544584
 43. Fontes A, Andreoli MA, Villa LL, Assone T, Gaester K, Fonseca LAM, et al. High specific immune response to a bivalent anti-HPV vaccine in HIV-1-infected men in São Paulo, Brazil. *Papillomavirus Res*. 2016;2:17-20. <https://doi.org/10.1016/j.pvr.2016.01.001> PMID: 29074177
 44. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. *N Engl J Med*. 2011;365(17):1576-85. <https://doi.org/10.1056/NEJMoa1010971> PMID: 22029979
 45. Washington University School of Medicine. The effect of HPV vaccination on recurrence rates in HIV patients with condylomata. St Louis: Washington University School of Medicine; 2016. Available from: <https://clinicaltrials.gov/ct2/show/NCT00941889>
 46. University of the Witwatersrand. Randomized, double blind trial of the quadrivalent HPV vaccine to improve responses to LEEP treatment of cervical HSIL. Johannesburg: University of the Witwatersrand; 2017. Available from: <https://clinicaltrials.gov/ct2/show/NCT01928225>
 47. Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). HPV (human papilloma virus) vaccination after treatment of anal intraepithelial neoplasia (AIN) (VACCAIN-P). Amsterdam: AMC-UVA; 2018. Available from: <https://clinicaltrials.gov/ct2/show/NCT02087384>
 48. European AIDS Clinical Society (EACS). Clinical management and treatment of HIV infected adults in Europe, version 8.0. Brussels: EACS; 2015. Available from: http://www.eacsociety.org/files/2015_eacsguidelines_8_0-english_rev-20160124.pdf
 49. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. [Accessed 3 Jul 2018]. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf.
 50. D'Souza G, Wiley DJ, Li X, Chmiel JS, Margolick JB, Cranston RD, et al. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. *J Acquir Immune Defic Syndr*. 2008;48(4):491-9. <https://doi.org/10.1097/QAI.0b013e31817aebfe> PMID: 18614927
 51. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. *Cancer*. 2004;101(2):270-80. <https://doi.org/10.1002/cncr.20365> PMID: 15241823
 52. Goldstone SE, Hundert JS, Huyett JW. Infrared coagulator ablation of high-grade anal squamous intraepithelial lesions in HIV-negative males who have sex with males. *Dis Colon Rectum*. 2007;50(5):565-75. <https://doi.org/10.1007/s10350-006-0874-x> PMID: 17380365
 53. Centers for Disease Control and Prevention (CDC). Sexually transmitted disease surveillance 2014. Atlanta: CDC; 2015. Available from: <http://www.cdc.gov/std/stats14/surv-2014-print.pdf>
 54. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. *N Engl J Med*. 2011;364(5):401-11. <https://doi.org/10.1056/NEJMoa0909537> PMID: 21288094
 55. Hillman RJ, Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Vardas E, et al. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. *Clin Vaccine Immunol*. 2012;19(2):261-7. <https://doi.org/10.1128/CVI.05208-11> PMID: 22155768
 56. Swedish KA, Goldstone SE. Prevention of anal condyloma with quadrivalent human papillomavirus vaccination of older men who have sex with men. *PLoS One*. 2014;9(4):e93393. <https://doi.org/10.1371/journal.pone.0093393> PMID: 24714693
 57. Swedish KA, Factor SH, Goldstone SE. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. *Clin Infect Dis*. 2012;54(7):891-8. <https://doi.org/10.1093/cid/cir1036> PMID: 22291111
 58. Castellsagué X, Giuliano AR, Goldstone S, Guevara A, Mogensen O, Palefsky JM, et al. Immunogenicity and safety of the 9-valent HPV vaccine in men. *Vaccine*. 2015;33(48):6892-901. <https://doi.org/10.1016/j.vaccine.2015.06.088> PMID: 26144901
 59. Seksik P, Cosnes J, Sokol H, Nion-Larmurier I, Gendre JP, Beaugerie L. Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. *Aliment Pharmacol Ther*. 2009;29(10):1106-13. <https://doi.org/10.1111/j.1365-2036.2009.03973.x> PMID: 19222411
 60. Somasekar A, Alcolado R. Genital condylomata in a patient receiving infliximab for Crohn's disease. *Postgrad Med J*. 2004;80(944):358-9. <https://doi.org/10.1136/pgmj.2003.009332> PMID: 15192172
 61. Antoniou C, Kosmadaki MG, Stratigos AJ, Katsambas AD. Genital HPV lesions and molluscum contagiosum occurring in patients receiving anti-TNF-alpha therapy. *Dermatology*. 2008;216(4):364-5. <https://doi.org/10.1159/000117709> PMID: 18285688
 62. Handisurya A, Lázár S, Papay P, Primas C, Haitel A, Horvat R, et al. Anogenital Human Papillomavirus Prevalence is Unaffected by Therapeutic Tumour Necrosis Factor-alpha Inhibition. *Acta Derm Venereol*. 2016;96(4):494-8. <https://doi.org/10.2340/00015555-2298> PMID: 26581127
 63. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. *Am J Gastroenterol*. 2008;103(3):631-6. <https://doi.org/10.1111/j.1572-0241.2007.01582.x> PMID: 17941962
 64. Bhatia J, Bratcher J, Korelitz B, Vakher K, Mannor S, Shevchuk M, et al. Abnormalities of uterine cervix in women

- with inflammatory bowel disease. *World J Gastroenterol*. 2006;12(38):6167-71. <https://doi.org/10.3748/wjg.v12.i38.6167> PMID: 17036389
65. Jess T, Horváth-Puhó E, Fallingborg J, Rasmussen HH, Jacobsen BA. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. *Am J Gastroenterol*. 2013;108(12):1869-76. <https://doi.org/10.1038/ajg.2013.249> PMID: 23978954
 66. Rungoe C, Simonsen J, Riis L, Frisch M, Langholz E, Jess T. Inflammatory bowel disease and cervical neoplasia: a population-based nationwide cohort study. *Clin Gastroenterol Hepatol*. 2015;13(4):693-700.e1.
 67. Singh H, Demers AA, Nugent Z, Mahmud SM, Kliewer EV, Bernstein CN. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. *Gastroenterology*. 2009;136(2):451-8. <https://doi.org/10.1053/j.gastro.2008.10.021> PMID: 18996382
 68. Lees CW, Critchley J, Chee N, Beez T, Gailer RE, Williams AR, et al. Lack of association between cervical dysplasia and IBD: a large case-control study. *Inflamm Bowel Dis*. 2009;15(11):1621-9. <https://doi.org/10.1002/ibd.20959> PMID: 19618462
 69. Jacobson DL, Bousvaros A, Ashworth L, Carey R, Shrier LA, Burchett SK, et al. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. *Inflamm Bowel Dis*. 2013;19(7):1441-9. <https://doi.org/10.1097/MIB.0b013e318281341b> PMID: 23567780
 70. Annes V, Beaugier L, Egan L, Biancone L, Bolling C, Brandts C, et al. ECCO. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. *J Crohn's Colitis*. 2015;9(11):945-65. <https://doi.org/10.1093/ecco-jcc/jjv141> PMID: 26294789
 71. Campins M, Cossio Y, Martínez X, Borrueal N. Vaccination of patients with inflammatory bowel disease. Practical recommendations. *Rev Esp Enferm Dig*. 2013;105(2):93-102. <https://doi.org/10.4321/S1130-01082013000200006> PMID: 23659508
 72. Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. *J Crohn's Colitis*. 2014;8(6):443-68. <https://doi.org/10.1016/j.crohns.2013.12.013> PMID: 24613021
 73. Magro F, Peyrin-Biroulet L, Sokol H, Aldeger X, Costa A, Higgins PD, et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). *J Crohn's Colitis*. 2014;8(1):31-44. <https://doi.org/10.1016/j.crohns.2013.04.006> PMID: 23721759
 74. Castellsagué X, Iftner T, Roura E, Vidart JA, Kjaer SK, Bosch FX, et al. Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: the CLEOPATRE study. *J Med Virol*. 2012;84(6):947-56. <https://doi.org/10.1002/jmv.23282> PMID: 22499018
 75. Torné Bladé A, Bayas Rodríguez JM, Castellsagué Piqué X, Castro Sánchez M, García García E, Martínez Escoriza JC, et al. Vacunación frente al cáncer de cérvix en mujeres fuera de los programas de vacunación sistemática, con o sin infección por el virus del papiloma humano o lesión cervical. Encuesta de opinión y recomendaciones. [Vaccination against cervical cancer in women outside of routine vaccination programs, with or without human papillomavirus infection or cervical lesion. Survey of opinion and recommendations]. *Prog Obs Ginecol*. 2012;55(Suppl 1):10-31. [https://doi.org/10.1016/S0304-5013\(12\)73065-0](https://doi.org/10.1016/S0304-5013(12)73065-0)
 76. Kocken M, Helmerhorst TJ, Berkhof J, Louwers JA, Nobbenhuis MA, Bais AG, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. *Lancet Oncol*. 2011;12(5):441-50. [https://doi.org/10.1016/S1470-2045\(11\)70078-X](https://doi.org/10.1016/S1470-2045(11)70078-X) PMID: 21530398
 77. Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. *Br J Cancer*. 2011;105(1):28-37. <https://doi.org/10.1038/bjc.2011.185> PMID: 21629249
 78. Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmerón J, et al. VIVIANE Study Group. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuncted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. *Lancet*. 2014;384(9961):2213-27. [https://doi.org/10.1016/S0140-6736\(14\)60920-X](https://doi.org/10.1016/S0140-6736(14)60920-X) PMID: 25189358
 79. Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. *BMJ*. 2012;344:e1401. PMID: 22454089
 80. Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? *Gynecol Oncol*. 2013;130(2):264-8. <https://doi.org/10.1016/j.ygyno.2013.04.050> PMID: 23623831
 81. Garland SM, Paavonen J, Jaisamrarn U, Naud P, Salmerón J, Chow SN, et al. Prior human papillomavirus-16/18 AS04-adjuncted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial. *Int J Cancer*. 2016;139(12):2812-26. <https://doi.org/10.1002/ijc.30391> PMID: 27541373
 82. Dokal I, Vulliamy T. Inherited aplastic anaemias/bone marrow failure syndromes. *Blood Rev*. 2008;22(3):141-53. <https://doi.org/10.1016/j.blre.2007.11.003> PMID: 18164793
 83. Leiding JW, Holland SM. Warts and all: human papillomavirus in primary immunodeficiencies. *J Allergy Clin Immunol*. 2012;130(5):1030-48. <https://doi.org/10.1016/j.jaci.2012.07.049> PMID: 23036745
 84. Savani BN, Stratton P, Shenoy A, Kozanas E, Goodman S, Barrett AJ. Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation-implications for screening and HPV vaccination. *Biol Blood Marrow Transplant*. 2008;14(9):1072-5. <https://doi.org/10.1016/j.bbmt.2008.07.005> PMID: 18721771
 85. Ojha RP, Tota JE, Offutt-Powell TN, Klosky JL, Minniear TD, Jackson BE, et al. Human papillomavirus-associated subsequent malignancies among long-term survivors of pediatric and young adult cancers. *PLoS One*. 2013;8(8):e70349. <https://doi.org/10.1371/journal.pone.0070349> PMID: 23940566
 86. Katzenellenbogen RA, Carter JJ, Stern JE, Butsch Kovacic MS, Mehta PA, Sauter SL, et al. Skin and mucosal human papillomavirus seroprevalence in persons with Fanconi Anemia. *Clin Vaccine Immunol*. 2015;22(4):413-20. <https://doi.org/10.1128/CVI.00665-14> PMID: 25651924
 87. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2006;55(RR-15):1-48. PMID: 17136024
 88. Handisurya A, Schellenbacher C, Reininger B, Koszik F, Vyhnaneck P, Heitger A, et al. A quadrivalent HPV vaccine induces humoral and cellular immune responses in WHIM immunodeficiency syndrome. *Vaccine*. 2010;28(30):4837-41. <https://doi.org/10.1016/j.vaccine.2010.04.057> PMID: 20472031
 89. Children's Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers - Version 4.0, October 2013. [Accessed 3 Jul 2018]. Available from: http://www.survivorshipguidelines.org/pdf/LTFUGuidelines_4.0.pdf
 90. Klosky JL, Foster RH, Hodges J, Peasant C, Gamble H, McDermott MJ, et al. Human papillomavirus vaccination and the primary prevention of cancer: implications for survivors of childhood cancer. *Stud Health Technol Inform*. 2012;172:33-42. PMID: 22910499
 91. Rose B, Wilkins D, Li W, Tran N, Thompson C, Cossart Y, et al. Human papillomavirus in the oral cavity of patients with and without renal transplantation. *Transplantation*. 2006;82(4):570-3. <https://doi.org/10.1097/01.tp.0000231706.79165.e5> PMID: 16926603
 92. Reuschenbach M, Tran T, Faulstich F, Hartschuh W, Vinokurova S, Kloor M, et al. High-risk human papillomavirus in non-melanoma skin lesions from renal allograft recipients and immunocompetent patients. *Br J Cancer*. 2011;104(8):1334-41. <https://doi.org/10.1038/bjc.2011.95> PMID: 21427726
 93. Meeuwis KA, Melchers WJ, Bouten H, van de Kerkhof PC, Hinten F, Quint WG, et al. Anogenital malignancies in women after renal transplantation over 40 years in a single center. *Transplantation*. 2012;93(9):914-22. <https://doi.org/10.1097/TP.0b013e318249b13d> PMID: 22377788
 94. Park ST, Song MJ, Park JS, Hur SY, Lee CW. Incidence and clinicopathologic behavior of uterine cervical carcinoma in renal transplant recipients. *World J Surg Oncol*. 2011;9(1):72. <https://doi.org/10.1186/1477-7819-9-72> PMID: 21752252
 95. Patel HS, Silver AR, Levine T, Williams G, Northover JM. Human papillomavirus infection and anal dysplasia in renal transplant recipients. *Br J Surg*. 2010;97(11):1716-21. <https://doi.org/10.1002/bjs.7218> PMID: 20730855
 96. Meeuwis KA, Hilbrands LB, Int'Hout J, Slangen BF, Hendriks IM, Hinten F, et al. Cervicovaginal HPV infection in female renal transplant recipients: an observational, self-sampling based,

- cohort study. *Am J Transplant*. 2015;15(3):723-33. PMID: 25675976
97. Adami J, Gäbel H, Lindelöf B, Ekström K, Rydh B, Glimelius B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. *Br J Cancer*. 2003;89(7):1221-7. <https://doi.org/10.1038/sj.bjc.6601219> PMID: 14520450
 98. Meeuwis KA, van Rossum MM, van de Kerkhof PC, Hoitsma AJ, Massuger LF, de Hullu JA. Skin cancer and (pre)malignancies of the female genital tract in renal transplant recipients. *Transpl Int*. 2010;23(2):191-9. <https://doi.org/10.1111/j.1432-2277.2009.00975.x> PMID: 19793075
 99. Kolb HJ, Socié G, Duell T, Van Lint MT, Tichelli A, Apperley JF, et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. *Ann Intern Med*. 1999;131(10):738-44. <https://doi.org/10.7326/0003-4819-131-10-199911160-00004> PMID: 10577296
 100. Bhatia S, Louie AD, Bhatia R, O'Donnell MR, Fung H, Kashyap A, et al. Solid cancers after bone marrow transplantation. *J Clin Oncol*. 2001;19(2):464-71. <https://doi.org/10.1200/JCO.2001.19.2.464> PMID: 11208840
 101. Rizzo JD, Curtis RE, Socié G, Sobocinski KA, Gilbert E, Landgren O, et al. Solid cancers after allogeneic hematopoietic cell transplantation. *Blood*. 2009;113(5):1175-83. <https://doi.org/10.1182/blood-2008-05-158782> PMID: 18971419
 102. Savani BN, Goodman S, Barrett AJ. Can routine posttransplant HPV vaccination prevent commonly occurring epithelial cancers after allogeneic stem cell transplantation? *Clin Cancer Res*. 2009;15(7):2219-21. <https://doi.org/10.1158/1078-0432.CCR-08-3099> PMID: 19293253
 103. Wang Y, Brinck L, Jebsen P, Tanbo T, Kirschner R. A clinical study of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation. *Biol Blood Marrow Transplant*. 2012;18(5):747-53. <https://doi.org/10.1016/j.bbmt.2011.09.012> PMID: 21963879
 104. Kumar D, Unger ER, Panicker G, Medvedev P, Wilson L, Humar A. Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients. *Am J Transplant*. 2013;13(9):2411-7. <https://doi.org/10.1111/ajt.12329> PMID: 23837399
 105. Gomez-Lobo V, Whyte T, Kaufman S, Torres C, Moudgil A. Immunogenicity of a prophylactic quadrivalent human papillomavirus L1 virus-like particle vaccine in male and female adolescent transplant recipients. *Pediatr Transplant*. 2014;18(3):310-5. <https://doi.org/10.1111/petr.12226> PMID: 24484551
 106. Nelson DR, Neu AM, Abraham A, Amaral S, Batsky D, Fadrowski JJ. Immunogenicity of Human Papillomavirus Recombinant Vaccine in Children with CKD. *Clin J Am Soc Nephrol*. 2016;11(5):776-84. <https://doi.org/10.2215/CJN.09690915> PMID: 27055465
 107. Palefsky JM, Gillison ML, Strickler HD. Chapter 16: HPV vaccines in immunocompromised women and men. *Vaccine*. 2006;24 Suppl 3:S3/140-6.
 108. Reusser NM, Downing C, Guidry J, Tyring SK. HPV Carcinomas in Immunocompromised Patients. *J Clin Med*. 2015;4(2):260-81. <https://doi.org/10.3390/jcm4020260> PMID: 26239127
 109. Grein IH, Groot N, Lacerda MI, Wulffraat N, Pileggi G. HPV infection and vaccination in Systemic Lupus Erythematosus patients: what we really should know. *Pediatr Rheumatol Online J*. 2016;14(1):12. <https://doi.org/10.1186/s12969-016-0072-x> PMID: 26956735
 110. Santana IU, Gomes AN, Lyrio LD, Rios Grassi MF, Santiago MB. Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review. *Clin Rheumatol*. 2011;30(5):665-72. <https://doi.org/10.1007/s10067-010-1606-0> PMID: 21072553
 111. Zard E, Arnaud L, Mathian A, Chakhtoura Z, Hie M, Touraine P, et al. Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta-analysis of the literature. *Autoimmun Rev*. 2014;13(7):730-5. <https://doi.org/10.1016/j.autrev.2014.03.001> PMID: 24657969
 112. Lyrio LD, Grassi MF, Santana IU, Olavarria VG, Gomes AN, CostaPinto L, et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. *Rheumatol Int*. 2013;33(2):335-40. <https://doi.org/10.1007/s00296-012-2426-0> PMID: 22451033
 113. Adams DR, Zaenglein AL, Hershey MS. Etanercept and warts. *J Drugs Dermatol*. 2004;3(6):601. PMID: 15624740
 114. Kim SY, Solomon DH. Tumor necrosis factor blockade and the risk of viral infection. *Nat Rev Rheumatol*. 2010;6(3):165-74. <https://doi.org/10.1038/nrrheum.2009.279> PMID: 20142812
 115. Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. *Ann Rheum Dis*. 2013;72(5):659-64. <https://doi.org/10.1136/annrheumdis-2012-201393> PMID: 22589375
 116. Heijstek MW, Scherpenisse M, Groot N, Wulffraat NM, Van Der Klis FR. Immunogenicity of the bivalent human papillomavirus vaccine in adolescents with juvenile systemic lupus erythematosus or juvenile dermatomyositis. *J Rheumatol*. 2013;40(9):1626-7. <https://doi.org/10.3899/jrheum.130246> PMID: 23997002
 117. Soybilic A, Onel KB, Utset T, Alexander K, Wagner-Weiner L. Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years. *Pediatr Rheumatol Online J*. 2013;11(1):29. <https://doi.org/10.1186/1546-0096-11-29> PMID: 23924237
 118. Heijstek MW, Scherpenisse M, Groot N, Tacke C, Schepp RM, Buisman AM, et al. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study. *Ann Rheum Dis*. 2014;73(8):1500-7. <https://doi.org/10.1136/annrheumdis-2013-203429> PMID: 23723319
 119. Esposito S, Corona F, Barzon L, Cuoco F, Squarzon L, Marcati G, et al. Immunogenicity, safety and tolerability of a bivalent human papillomavirus vaccine in adolescents with juvenile idiopathic arthritis. *Expert Rev Vaccines*. 2014;13(11):1387-93. <https://doi.org/10.1586/14760584.2014.943195> PMID: 25066387
 120. van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. *Ann Rheum Dis*. 2011;70(3):414-22. <https://doi.org/10.1136/ard.2010.137216> PMID: 21131643
 121. Carifi M, Napolitano D, Morandi M, Dall'Olio D. Recurrent respiratory papillomatosis: current and future perspectives. *Ther Clin Risk Manag*. 2015;11:731-8. <https://doi.org/10.2147/TCRM.S81825> PMID: 25999724
 122. Chirilă M, Bolboacă SD. Clinical efficiency of quadrivalent HPV (types 6/11/16/18) vaccine in patients with recurrent respiratory papillomatosis. *Eur Arch Otorhinolaryngol*. 2014;271(5):1135-42. <https://doi.org/10.1007/s00405-013-2755-y> PMID: 24121781
 123. Lindeberg H, Elbrønd O. Laryngeal papillomas: the epidemiology in a Danish subpopulation 1965-1984. *Clin Otolaryngol Allied Sci*. 1990;15(2):125-31. <https://doi.org/10.1111/j.1365-2273.1990.tb00444.x> PMID: 2350888
 124. Derkay CS. Task force on recurrent respiratory papillomas. A preliminary report. *Arch Otolaryngol Head Neck Surg*. 1995;121(12):1386-91. <https://doi.org/10.1001/archotol.1995.01890120044008> PMID: 7488368
 125. Förster G, Boltze C, Seidel J, Pawlita M, Müller A. [Juvenile laryngeal papillomatosis--immunisation with the polyvalent vaccine gardasil]. *Laryngorhinootologie*. 2008;87(11):796-9. PMID: 18759217
 126. Young DL, Moore MM, Halstead LA. The use of the quadrivalent human papillomavirus vaccine (gardasil) as adjuvant therapy in the treatment of recurrent respiratory papilloma. *J Voice*. 2015;29(2):223-9. <https://doi.org/10.1016/j.jvoice.2014.08.003> PMID: 25619468
 127. Mudry P, Vavrina M, Mazanek P, Machalova M, Litzman J, Sterba J. Recurrent laryngeal papillomatosis: successful treatment with human papillomavirus vaccination. *Arch Dis Child*. 2011;96(5):476-7. <https://doi.org/10.1136/adc.2010.198184> PMID: 21220258
 128. Mészner Z, Jankovics I, Nagy A, Gerlinger I, Katona G. Recurrent laryngeal papillomatosis with oesophageal involvement in a 2 year old boy: successful treatment with the quadrivalent human papillomatosis vaccine. *Int J Pediatr Otorhinolaryngol*. 2015;79(2):262-6. <https://doi.org/10.1016/j.ijporl.2014.11.022> PMID: 25496821
 129. Yi L, Vaudaux B, Sandu K, Nisa L. Prolonged remission of juvenile-onset respiratory papillomatosis: a post-expositional role of the tetravalent anti-HPV vaccine? *Int J Pediatr Otorhinolaryngol*. 2014;78(2):388-90. <https://doi.org/10.1016/j.ijporl.2013.12.013> PMID: 24388316
 130. Hočevár-Boltežar I, Matičič M, Sereg-Bahar M, Gale N, Poljak M, Kocjan B, et al. Human papilloma virus vaccination in patients with an aggressive course of recurrent respiratory papillomatosis. *Eur Arch Otorhinolaryngol*. 2014;271(12):3255-62. <https://doi.org/10.1007/s00405-014-3143-y> PMID: 24964770
 131. Hermann JS, Weckx LY, Monteiro Nürnberger J, Santos Junior GF, Campos Pignatari AC, Nagata Pignatari SS. Effectiveness of the human papillomavirus (types 6, 11, 16, and 18) vaccine in the treatment of children with recurrent respiratory papillomatosis. *Int J Pediatr Otorhinolaryngol*. 2016;83:94-8. <https://doi.org/10.1016/j.ijporl.2016.01.032> PMID: 26968061

132. Pawlita M, Gissmann L. Rekurrierende respiratorische Papillomatose [Recurrent respiratory papillomatosis]. Dtsch Med Wochenschr. 2009;134:S100-S102. PMID: 19353471

License and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.

This article is copyright of the authors or their affiliated institutions, 2019.